马来酸桂哌齐特注射液治疗缺血性脑卒中的临床疗效及其对血清白介素6、基质金属蛋白酶9、超敏 C 反应蛋白的水平影响

摘要

Objective To analyze the clinical effect of cinepazide maleate injection on ischemic stroke and the impact on serum levels of IL-6,MMP-9 and hs-CRP. Methods A total of 95 patients with ischemic stroke were selected in Hu'nan Provincial People's Hospital from September 2013 to September 2015,and they were divided into control group(n = 47) and observation group(n = 48) according to random number table. Patients of control group received conventional treatment after admission,while patients of observation group received extra cinepazide maleate injection based on conventional treatment;both groups continuously treated for 14 days. Clinical effect,NIHSS score,Barthel index and serum levels of IL-6,MMP-9 and hs-CRP before and after treatment,and incidence of adverse reactions were compared between the two groups. Results The clinical effect of observation group was statistically significantly better than that of control group( P ﹤ 0. 05). No statistically significant differences of NIHSS score or Barthel index was found between the two groups before treatment( P ﹥ 0. 05);after treatment,NIHSS score of observation group was statistically significantly lower than that of control group,while Barthel index of observation group was statistically significantly higher than that of control group ( P ﹤ 0. 05 ). No statistically significant differences of serum level of IL-6,MMP-9 or hs-CRP was found between the two groups before treatment( P ﹥ 0. 05),while serum levels of IL-6,MMP-9 and hs-CRP of observation group were statistically significantly lower than those of control group after treatment(P ﹤ 0. 05). No one of the two groups occurred any serious adverse reactions during the treatment. Conclusion Cinepazide maleate injection has certain clinical effect in treating ischemic stroke,can effectively improve the neurological function and quality of life,reduce the serum levels of IL-6,MMP-9 and hs-CRP,and is relatively safe.%目的：分析马来酸桂哌齐特注射液治疗缺血性脑卒中的临床疗效及其对血清白介素6（IL-6）、基质金属蛋白酶9（MMP-9）、超敏 C 反应蛋白（hs-CRP）水平的影响。方法选取2013年9月—2015年9月湖南省人民医院收治的缺血性脑卒中患者95例，按随机数字表法分为对照组47例与观察组48例。对照组患者予以常规治疗，观察组患者在对照组基础上加用马来酸桂哌齐特注射液治疗；两组患者均连续治疗14 d。比较两组患者临床疗效，治疗前后美国国立卫生研究院卒中量表（NIHSS）评分、Barthel 指数和血清 IL-6、MMP-9、hs-CRP水平，不良反应发生情况。结果观察组患者临床疗效优于对照组（P ﹤0.05）。治疗前两组患者 NIHSS 评分、Barthel 指数比较，差异无统计学意义（P ﹥0.05）；治疗后观察组患者 NIHSS 评分低于对照组，Barthel 指数高于对照组（P ﹤0.05）。治疗前两组患者血清 IL-6、MMP-9、hs-CRP水平比较，差异无统计学意义（P ﹥0.05）；治疗后观察组患者血清 IL-6、MMP-9、hs-CRP水平低于对照组（P ﹤0.05）。两组患者均未发生严重不良反应。结论马来酸桂哌齐特注射液治疗缺血性脑卒中的临床疗效确切，可有效改善患者神经功能，提高患者生活质量，降低血清 IL-6、MMP-9、hs-CRP水平，且安全性较高。